Astria Therapeutics
ATXS
ATXS was delisted on the 22nd of January, 2026.
103 hedge funds and large institutions have $622M invested in Astria Therapeutics in 2024 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 33 increasing their positions, 38 reducing their positions, and 11 closing their positions.
36% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 11
23% more capital invested
Capital invested by funds: $506M → $622M (+$116M)
3% more funds holding
Funds holding: 100 → 103 (+3)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
1.07% less ownership
Funds ownership: 101.22% → 100.15% (-1.1%)
13% less repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 38
37% less call options, than puts
Call options by funds: $482K | Put options by funds: $769K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$19.7M |
| 2 |
VPC
Vestal Point Capital
New York
|
+$8.34M |
| 3 |
Millennium Management
New York
|
+$7.16M |
| 4 |
RG
Redmile Group
San Francisco,
California
|
+$3.46M |
| 5 |
Invesco
Atlanta,
Georgia
|
+$3.34M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
-$8.63M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$6.93M |
| 3 |
State Street
Boston,
Massachusetts
|
-$5.51M |
| 4 |
AAA
Affinity Asset Advisors
New York
|
-$2.79M |
| 5 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$2.56M |
ATXS Hedge Fund Activity: Q3 2024 in Review
103 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in Astria Therapeutics (ATXS) for Q3 2024, worth a combined $622M — up 23% from $506M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new ATXS positions and 11 closed out — a net gain of 4 holders — while 33 added to existing stakes and 38 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $19.7M. The largest seller was Vivo Capital, cutting an estimated $8.63M.
- 103 institutional investors held Astria Therapeutics (ATXS) as of Q3 2024, up from 100 in Q2 2024.
- Funds reported $622M of Astria Therapeutics stock for Q3 2024, up 23% quarter-over-quarter.
- 15 funds opened new Astria Therapeutics positions in Q3 2024 and 11 closed out, a net change of +4 holders.
- The largest Astria Therapeutics buyer in Q3 2024 was Fidelity Investments, an estimated $19.7M added.
- The largest Astria Therapeutics seller in Q3 2024 was Vivo Capital, an estimated $8.63M sold.
Based on aggregated 13F filings for Q3 2024.